ClinicalTrials.gg
CompletedNCT04924114Updated Aug 29, 2025Results posted

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

A Phase 1 interventional study of MK-6194 and MK-6194-matching placebo in Ulcerative Colitis, sponsored by Merck Sharp & Dohme LLC. Completed at 17 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Colitis, Ulcerative by Merck & Co., Inc — 2 open to participants now, 3 under way, 2 of them phase 3. Colitis, Ulcerative · Merck & Co., Inc.

Enrollment
8th of 11
57 · median 100
Started
2021
with 1 other
Phase 1
2 of 13
none open now
Registered
8th of 13
by date

Among the 13 studies in Colitis, Ulcerative by Merck & Co., Inc, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 8th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 13 studies in Colitis, Ulcerative by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Colitis, Ulcerative by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of UC at least 3 months prior to screening.
  • Mildly to severely active UC.
  • Inadequate response, loss of response, or intolerance to at least 1 prior conventional therapy, and no more than 2 prior advanced therapies.
  • Participants at risk for colorectal cancer must have a colonoscopy prior to or at screening as follows:

    • Participants > 50 years of age must have documentation of a colonoscopy within 3 years of the screening visit to exclude adenomatous polyps. Participants whose adenomas have been completely excised at screening are eligible.
    • Participants with extensive colitis for ≥ 8 years, or disease limited to the left side of the colon for ≥ 10 years, must either have had a full colonoscopy to assess for the presence of dysplasia within 1 year before first administration of study drug or a full colonoscopy to assess for the presence of at the screening visit.
  • No evidence of active tuberculosis (TB), latent TB, or inadequately treated TB.
  • Women of (WOCBP) and males with female partners of childbearing potential must utilize highly effective methods beginning 4 weeks prior to first dose of study drug and continue for 30 days after the last dose of study drug.
  • (BMI) 18 to 35 kg/m\^2 inclusive and weight ≥ 50 kg.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with recombinant IL-2 or modified IL-2 therapy, including MK-6194 (PT101).
  • Known sensitivity to MK-6194 (PT101) or its .
  • Known history of to interleukin-2 (IL-2).
  • Disease limited to the rectum (i.e., within 15 cm of the anal verge).
  • Diagnosis of toxic megacolon.
  • Suspected or known colon stricture or stenosis.
  • Diagnosis of Crohn's disease, or indeterminant colitis.
  • Has severe colitis as evidenced by:

    • Current hospitalization for the treatment of UC
    • Likely to require a colectomy within 12 weeks of baseline in the opinion of the Investigator
    • At least 4 symptoms of severe colitis as identified at screening or baseline visits.
  • Previously had surgery for UC, or likely to require surgery for UC during the study period in the opinion of the Investigator.
  • History of abnormal thallium stress test or functional cardiac function test.
  • History of significant cardiac, pulmonary, renal, hepatic, or central nervous system (CNS) impairment.
  • Active infection, or any infection requiring hospitalization or treatment with intravenous anti-infectives within 8 weeks of randomization, or any infection requiring oral anti-infective therapy within 6 weeks of randomization.
  • History of opportunistic infection.
  • History of symptomatic herpes zoster within 16 weeks of randomization, or any history of disseminated herpes simplex, disseminated herpes zoster, ophthalmic zoster, or central nervous system (CNS) zoster.
  • Currently on any chronic systemic (oral or IV) anti-infective therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).
  • Currently receiving lymphocyte depleting therapy.
  • History of abnormal pulmonary function tests.
  • Participants with organ or tissue allograft.
  • within 5 years of screening, with the exception of adequately treated or excised non- basal cell or squamous cell cancer of the skin.
  • Exposure to advanced therapy within 5 half-lives of the Day 1 visit, or documentation of detectable drug during screening.
  • Received a \< 1 month prior to screening or is planning to receive a live attenuated vaccine during the study period or within 12 weeks of the end of participation in the study.
  • Is pregnant or nursing or is planning to become pregnant during the study.
  • Any uncontrolled or clinically significant concurrent systemic disease other than UC.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    MK-6194 Low Dose - Interval 1 (Less Frequent)

    Participants received low dose of MK-6194 at specified less frequent intervals

    Drug: MK-6194

  • Experimental
    MK-6194 Medium Dose- Interval 2 (More Frequent)

    Participants received medium dose of MK-6194 at specified more frequent intervals

    Drug: MK-6194

  • Experimental
    MK-6194 High Dose- Interval 2 (More Frequent)

    Participants received high dose of MK-6194 at specified more frequent intervals

    Drug: MK-6194

  • Experimental
    MK-6194 High Dose- Interval 1 (Less Frequent)

    Participants received high dose MK-6194 at specified less frequent intervals

    Drug: MK-6194

  • Placebo comparator
    Placebo

    Participants received MK- 6194-matching placebo via subcutaneous injection, administered either at interval 1 or interval 2

    Drug: MK-6194-matching placebo

Interventions

  • Subcutaneous injection

    Also known as: PT101

  • DrugMK-6194-matching placebo

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 85 days

  2. Number of Participants Who Interrupted or Discontinued Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to thestudy intervention

    Time frame: Up to approximately 72 days

Secondary outcomes

  1. Maximum Concentration (Cmax) of MK-6194

    Blood samples were collected at pre-specified time points to determine each participant's maximum concentration (Cmax). A participant's Cmax was defined as the maximum concentration of MK-6194 observed in serum over the entire course of the study for that individual and was calculated by taking the maximum over all observed MK-6194 serum concentrations. Geometric mean and geometric coefficient of variation of Cmax were calculated for each dosing group.

    Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85.

  2. Time to Cmax (Tmax) of MK-6194

    Blood samples were collected at pre-specified time points to determine maximum concentration (Cmax) of MK-6194 in each participant's serum and corresponding time of maximum concentration (Tmax). A participant's Tmax was defined as the time post-dose that the maximum concentration of MK-6194 was observed in serum. The median and range of Tmax were calculated for each dosing group.

    Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85

  3. Minimum Concentration (Cmin) of MK-6194

    Blood samples were collected at pre-specified time points to determine the minimum concentration (Cmin) of MK-6194 present in each participant's serum. A participant's Cmin was defined as the minimum concentration of MK-6194 observed in serum over the entire course of the study for that individual and was calculated by taking the minimum over all observed MK-6194 serum concentrations. Geometric mean and geometric coefficient of variation of Cmin were calculated for each dosing group.

    Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85

  4. Apparent Half-life (t1/2) of MK-6194

    Blood samples were collected at pre-specified time points to determine the apparent half-life (t1/2) of MK-6194. Noncompartmental analysis was used to calculate t1/2 for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of t1/2 were calculated for each dosing group.

    Time frame: Final day of dosing at 12, 24-48 hours, and 120 hours (as available) post-dose; from the last day of dosing once each week up to approximately day 85

  5. Apparent Clearance (CL/F) of MK-6194

    Blood samples were collected at pre-specified time points to determine the apparent clearance (CL/F) of MK-6194 observed in serum. Noncompartmental analysis was used to calculate CL/F for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of CL/F were calculated for each dosing group.

    Time frame: Final day of dosing at 12, 24-48 hours, and 120 hours (as available) post-dose; from the last day of dosing once each week up to approximately day 85

  6. Apparent Volume of Distribution (Vd/F) of MK-6194

    Blood samples were collected at pre-specified time points to determine the apparent volume of distribution (Vd/F) of MK-6194 observed in serum. Noncompartmental analysis was used to calculate Vd/F for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of Vd/F were calculated for each dosing group.

    Time frame: Final day of dosing at 12, 24-48 hours, and 120 hours (as available) post-dose; from the last day of dosing once each week up to approximately day 85

  7. Area Under the Concentration Time-curve From Time 0 to the Last Quantifiable Concentration (AUC0-t)

    Blood samples were collected at pre-specified timepoints to determine the AUC0-t of MK-6194. AUC0-t is defined as the area under the concentration-time curve from time=0 (Day 1 predose) to the last quantifiable concentration. Noncompartmental analysis was used to calculate AUC0-t for each participant. Geometric mean and geometric coefficient of variation of AUC0-t were calculated for each dosing group.

    Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85

  8. Area Under the Curve From Time 0 to Infinity (AUC0-inf) of MK-6194

    Blood samples were collected at pre-specified timepoints to determine the AUC0-inf of MK-6194. AUC0-inf is defined as the area under the concentration-time curve from time=0 (Day 1 predose) to time=infinity. Noncompartmental analysis was used to calculate AUC0-inf for each participant; the portion of the AUC following the last observed concentration was assumed to follow an exponential elimination. Geometric mean and geometric coefficient of variation of AUC0-inf were calculated for each dosing group.

    Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85

  9. Change in Number of Peripheral Regulatory T-cells (Tregs) in Whole Blood

    Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The absolute change in the number of peripheral Tregs in whole blood was assessed.

    Time frame: Pre-dose (baseline) and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  10. Change in Number of Natural Killer (NK) Cells in Whole Blood

    Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The change in the number of NK cells in whole blood is presented.

    Time frame: Pre-dose (baseline) and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  11. Change in Number of Conventional T Cells (Tcons) in Whole Blood

    Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The change in the number of Tcons in whole blood is presented.

    Time frame: Pre-dose (baseline) and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  12. Titer of Anti-drug Antibody (ADA) to MK-6194

    Blood samples were collected for the determination of ADA to MK-6194 using a screening assay, ADA titer using a confirmatory assay, and neutralizing antibody to MK-6194 in participants with confirmed positive titers

    Time frame: Pre dose (week 0) and Weeks 4, 8, 12

07

Results

Posted Mar 24, 2025

Participant flow

Upon concluding the Initial Blinded Treatment (IBT) phase, participants could either complete the study or enter one of the next 2 phases. Participants who achieved clinical response could enter the continued blinded treatment (CBT) phase and continue receiving the same treatment as the IBT phase. Participants who did not achieve clinical response could enter an open label (OL) phase and receive MK-6194 at the same dose/regimen of their IBT cohort for active MK-6194 treatment.

Participant flow — Overall Study
MilestoneMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Started711181011
Continued in cbt phase21233
Treated in cbt phase21233
Continued in ol phase23402
Treated in ol phase34400
Completed7916109
Not completed02202
Withdrew: Withdrawal by subject02202

Outcome measures

SecondaryMaximum Concentration (Cmax) of MK-6194

Blood samples were collected at pre-specified time points to determine each participant's maximum concentration (Cmax). A participant's Cmax was defined as the maximum concentration of MK-6194 observed in serum over the entire course of the study for that individual and was calculated by taking the maximum over all observed MK-6194 serum concentrations. Geometric mean and geometric coefficient of variation of Cmax were calculated for each dosing group.

Time frame:
Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85.
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of MK-6194
ng/mLMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Maximum Concentration (Cmax) of MK-61949.55 ± 67.8030.02 ± 95.8551.80 ± 71.9752.78 ± 178.96—
SecondaryTime to Cmax (Tmax) of MK-6194

Blood samples were collected at pre-specified time points to determine maximum concentration (Cmax) of MK-6194 in each participant's serum and corresponding time of maximum concentration (Tmax). A participant's Tmax was defined as the time post-dose that the maximum concentration of MK-6194 was observed in serum. The median and range of Tmax were calculated for each dosing group.

Time frame:
Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85
Reported as:
Median · hours
Time to Cmax (Tmax) of MK-6194
hoursMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Time to Cmax (Tmax) of MK-619412.00 (11.10 to 24.00)12.00 (11.50 to 24.50)12.05 (11.10 to 25.00)12.10 (11.20 to 12.20)—
SecondaryMinimum Concentration (Cmin) of MK-6194

Blood samples were collected at pre-specified time points to determine the minimum concentration (Cmin) of MK-6194 present in each participant's serum. A participant's Cmin was defined as the minimum concentration of MK-6194 observed in serum over the entire course of the study for that individual and was calculated by taking the minimum over all observed MK-6194 serum concentrations. Geometric mean and geometric coefficient of variation of Cmin were calculated for each dosing group.

Time frame:
Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85
Reported as:
Geometric mean · ng/mL
Minimum Concentration (Cmin) of MK-6194
ng/mLMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Minimum Concentration (Cmin) of MK-61940.08 ± 0.000.08 ± 0.000.09 ± 97.700.08 ± 0.00—
SecondaryApparent Half-life (t1/2) of MK-6194

Blood samples were collected at pre-specified time points to determine the apparent half-life (t1/2) of MK-6194. Noncompartmental analysis was used to calculate t1/2 for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of t1/2 were calculated for each dosing group.

Time frame:
Final day of dosing at 12, 24-48 hours, and 120 hours (as available) post-dose; from the last day of dosing once each week up to approximately day 85
Reported as:
Geometric mean · hours
Apparent Half-life (t1/2) of MK-6194
hoursMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Apparent Half-life (t1/2) of MK-6194193.28 ± 66.5152.84 ± 23.8942.06 ± 80.4196.09 ± 16.51—
SecondaryApparent Clearance (CL/F) of MK-6194

Blood samples were collected at pre-specified time points to determine the apparent clearance (CL/F) of MK-6194 observed in serum. Noncompartmental analysis was used to calculate CL/F for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of CL/F were calculated for each dosing group.

Time frame:
Final day of dosing at 12, 24-48 hours, and 120 hours (as available) post-dose; from the last day of dosing once each week up to approximately day 85
Reported as:
Geometric mean · L/hours
Apparent Clearance (CL/F) of MK-6194
L/hoursMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Apparent Clearance (CL/F) of MK-61940.00 ± 66.280.01 ± 82.720.01 ± 95.070.01 ± 78.70—
SecondaryApparent Volume of Distribution (Vd/F) of MK-6194

Blood samples were collected at pre-specified time points to determine the apparent volume of distribution (Vd/F) of MK-6194 observed in serum. Noncompartmental analysis was used to calculate Vd/F for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of Vd/F were calculated for each dosing group.

Time frame:
Final day of dosing at 12, 24-48 hours, and 120 hours (as available) post-dose; from the last day of dosing once each week up to approximately day 85
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vd/F) of MK-6194
LitersMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Apparent Volume of Distribution (Vd/F) of MK-61941.61 ± 121.120.82 ± 96.990.55 ± 226.960.81 ± 93.17—
SecondaryArea Under the Concentration Time-curve From Time 0 to the Last Quantifiable Concentration (AUC0-t)

Blood samples were collected at pre-specified timepoints to determine the AUC0-t of MK-6194. AUC0-t is defined as the area under the concentration-time curve from time=0 (Day 1 predose) to the last quantifiable concentration. Noncompartmental analysis was used to calculate AUC0-t for each participant. Geometric mean and geometric coefficient of variation of AUC0-t were calculated for each dosing group.

Time frame:
Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85
Reported as:
Geometric mean · ng*hour/mL
Area Under the Concentration Time-curve From Time 0 to the Last Quantifiable Concentration (AUC0-t)
ng*hour/mLMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Area Under the Concentration Time-curve From Time 0 to the Last Quantifiable Concentration (AUC0-t)955.51 ± 39.922080.46 ± 55.643546.54 ± 67.173203.50 ± 117.92—
SecondaryArea Under the Curve From Time 0 to Infinity (AUC0-inf) of MK-6194

Blood samples were collected at pre-specified timepoints to determine the AUC0-inf of MK-6194. AUC0-inf is defined as the area under the concentration-time curve from time=0 (Day 1 predose) to time=infinity. Noncompartmental analysis was used to calculate AUC0-inf for each participant; the portion of the AUC following the last observed concentration was assumed to follow an exponential elimination. Geometric mean and geometric coefficient of variation of AUC0-inf were calculated for each dosing group.

Time frame:
Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85
Reported as:
Geometric mean · ng*hour/mL
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of MK-6194
ng*hour/mLMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of MK-6194899.08 ± 36.532036.51 ± 71.463437.33 ± 65.593169.11 ± 120.37—
SecondaryChange in Number of Peripheral Regulatory T-cells (Tregs) in Whole Blood

Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The absolute change in the number of peripheral Tregs in whole blood was assessed.

Time frame:
Pre-dose (baseline) and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Geometric mean · Cells/uL
Change in Number of Peripheral Regulatory T-cells (Tregs) in Whole Blood
Cells/uLMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Week 116.6 ± 46.1024.0 ± 130.3436.5 ± 76.6831.0 ± 48.950.0 ± 107.20
Week 215.2 ± 45.438.4 ± 78.560.0 ± 84.5229.8 ± 100.536.0 ± 109.31
Week 312.2 ± 113.8324.5 ± 95.4031.7 ± 92.2415.2 ± 77.364.4 ± 96.26
Week 45.1 ± 71.209.5 ± 78.3112.8 ± 82.294.8 ± 115.020.0 ± 120.87
Week 533.9 ± 61.550.0 ± 66.6320.9 ± 78.6335.5 ± 65.560.0 ± 92.71
Week 69.0 ± 32.7312.9 ± 73.279.8 ± 100.1618.9 ± 58.450.0 ± 61.81
Week 74.0 ± 53.2932.3 ± 44.5127.1 ± 69.987.4 ± 130.110.0 ± 66.82
Week 83.9 ± 25.009.4 ± 101.408.8 ± 62.207.7 ± 101.490.0 ± 102.85
Week 96.0 ± 121.2421.1 ± 76.4522.3 ± 83.2842.1 ± 63.994.3 ± 101.64
Week 102.3 ± 24.7415.4 ± 55.4211.3 ± 76.1116.3 ± 91.233.5 ± 146.88
Week 11—17.8 ± 79.9024.6 ± 82.30—3.5 ± 117.48
Week 125.9 ± 16.6712.1 ± 56.516.4 ± 89.540.0 ± 77.224.7 ± 91.20
SecondaryChange in Number of Natural Killer (NK) Cells in Whole Blood

Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The change in the number of NK cells in whole blood is presented.

Time frame:
Pre-dose (baseline) and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Geometric mean · Cells/uL
Change in Number of Natural Killer (NK) Cells in Whole Blood
Cells/uLMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Week 1109.3 ± 117.560.0 ± 149.4343.2 ± 86.39110.0 ± 61.9034.40 ± 60.38
Week 2124.7 ± 83.3276.1 ± 62.7748.6 ± 81.20108.5 ± 55.4819.2 ± 160.68
Week 3479.5 ± 85.5150.3 ± 73.7944.2 ± 110.6168.4 ± 62.2064.1 ± 87.37
Week 4292.2 ± 48.3852.8 ± 67.480.0 ± 102.8378.9 ± 73.4042.1 ± 131.09
Week 5281.5 ± 27.4342.1 ± 76.3453.8 ± 61.16133.2 ± 87.9665.0 ± 129.61
Week 6169.0 ± 88.1159.3 ± 72.5654.7 ± 80.71140.3 ± 78.1055.3 ± 124.75
Week 7224.8 ± 83.090.0 ± 112.8573.2 ± 66.1682.0 ± 93.6244.9 ± 119.10
Week 8272.9 ± 54.6238.4 ± 113.4643.7 ± 148.3786.9 ± 49.1030.4 ± 125.05
Week 9195.5 ± 4.3592.8 ± 94.0472.8 ± 74.2094.0 ± 75.8653.2 ± 81.75
Week 10159.6 ± 59.8626.4 ± 83.2546.0 ± 111.1287.1 ± 99.3884.5 ± 91.34
Week 11—42.3 ± 94.1947.0 ± 91.92—41.1 ± 163.74
Week 1270.6 ± 125.6167.6 ± 60.5658.4 ± 84.3945.6 ± 119.5840.9 ± 121.60
SecondaryChange in Number of Conventional T Cells (Tcons) in Whole Blood

Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The change in the number of Tcons in whole blood is presented.

Time frame:
Pre-dose (baseline) and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Geometric mean · Cells/uL
Change in Number of Conventional T Cells (Tcons) in Whole Blood
Cells/uLMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Week 1216.9 ± 94.52220.8 ± 94.3791.2 ± 105.12189.6 ± 66.5857.6 ± 79.00
Week 2106.1 ± 124.15100.8 ± 67.50105.4 ± 121.23184.1 ± 67.770.0 ± 71.58
Week 3347.3 ± 129.7681.1 ± 98.95123.7 ± 111.06192.8 ± 60.55127.7 ± 52.96
Week 4280.2 ± 116.12122.4 ± 61.7173.3 ± 108.47163.4 ± 72.0663.3 ± 105.58
Week 5456.3 ± 28.23100.6 ± 74.36126.2 ± 75.69166.8 ± 76.1979.3 ± 66.49
Week 6114.3 ± 119.1857.9 ± 101.250.0 ± 101.48193.9 ± 68.5953.8 ± 90.84
Week 7137.7 ± 84.27103.6 ± 68.2268.6 ± 87.88154.5 ± 70.6466.1 ± 87.17
Week 8381.1 ± 34.64109.0 ± 84.2863.5 ± 82.18159.1 ± 66.1250.6 ± 93.80
Week 9250.3 ± 39.38164.1 ± 51.01128.8 ± 89.61192.2 ± 71.43141.5 ± 63.25
Week 10271.1 ± 81.5033.4 ± 115.4450.7 ± 98.06147.3 ± 72.3183.2 ± 92.61
Week 11—76.1 ± 59.2090.5 ± 80.69—102.0 ± 45.66
Week 12122.6 ± 134.2073.2 ± 96.9499.9 ± 77.32153.3 ± 70.0373.4 ± 82.45
SecondaryTiter of Anti-drug Antibody (ADA) to MK-6194

Blood samples were collected for the determination of ADA to MK-6194 using a screening assay, ADA titer using a confirmatory assay, and neutralizing antibody to MK-6194 in participants with confirmed positive titers

Time frame:
Pre dose (week 0) and Weeks 4, 8, 12
Reported as:
Median · Titer
Titer of Anti-drug Antibody (ADA) to MK-6194
TiterMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Week 0—20.0 (20.0 to 20.0)—20.0 (20.0 to 20.0)—
Week 4—20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)20.0 (20.0 to 160.0)—
Week 8160.0 (160.0 to 160.0)20.0 (20.0 to 20.0)20.0 (20.0 to 20.0)20.0 (20.0 to 40.0)—
Week 12640.0 (640.0 to 640.0)40.0 (20.0 to 320.0)20.0 (20.0 to 640.0)40.0 (20.0 to 160.0)—
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to approximately 85 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Number of Participants Who Experienced an Adverse Event (AE)71018107
PrimaryNumber of Participants Who Interrupted or Discontinued Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to thestudy intervention

Time frame:
Up to approximately 72 days
Reported as:
Count of participants · Participants
Number of Participants Who Interrupted or Discontinued Study Treatment Due to an AE
ParticipantsMK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)Placebo
Number of Participants Who Interrupted or Discontinued Study Treatment Due to an AE10201

Adverse events

Collected over Up to approximately 52 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IBT: MK-6194 Low Dose Interval 1 (Less Frequent)0/7 (0%)1/7 (14.3%)7/7 (100%)
IBT-MK-6194 Medium Dose- Interval 2 (More Frequent)0/11 (0%)0/11 (0%)10/11 (90.9%)
IBT: MK-6194 High Dose-Interval 2 (More Frequent)0/18 (0%)1/18 (5.6%)18/18 (100%)
IBT:MK-6194 High Dose-Interval 1 (Less Frequent)0/10 (0%)0/10 (0%)10/10 (100%)
IBT: Placebo0/11 (0%)0/11 (0%)7/11 (63.6%)
CBT: MK-6194 Low Dose- Interval 1 (Less Frequent)0/2 (0%)0/2 (0%)2/2 (100%)
CBT: MK-6194 Medium Dose- Interval 2 (More Frequent)0/1 (0%)0/1 (0%)1/1 (100%)
CBT: MK-6194 High Dose- Interval 2 (More Frequent)0/2 (0%)0/2 (0%)2/2 (100%)
CBT: MK-6194 High Dose - Interval 1 (Less Frequent)0/3 (0%)0/3 (0%)2/3 (66.7%)
CBT: Placebo0/3 (0%)0/3 (0%)1/3 (33.3%)
OL: MK-6194 Low Dose -Interval 1 (Less Frequent)0/3 (0%)0/3 (0%)1/3 (33.3%)
OL: MK-6194 Medium Dose- Interval 2 (More Frequent)0/4 (0%)0/4 (0%)3/4 (75%)
OL: MK-6194 High Dose- Interval 2 (More Frequent)0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventIBT: MK-6194 Low Dose Interval 1 (Less Frequent)IBT-MK-6194 Medium Dose- Interval 2 (More Frequent)IBT: MK-6194 High Dose-Interval 2 (More Frequent)IBT:MK-6194 High Dose-Interval 1 (Less Frequent)IBT: PlaceboCBT: MK-6194 Low Dose- Interval 1 (Less Frequent)CBT: MK-6194 Medium Dose- Interval 2 (More Frequent)CBT: MK-6194 High Dose- Interval 2 (More Frequent)CBT: MK-6194 High Dose - Interval 1 (Less Frequent)CBT: PlaceboOL: MK-6194 Low Dose -Interval 1 (Less Frequent)OL: MK-6194 Medium Dose- Interval 2 (More Frequent)OL: MK-6194 High Dose- Interval 2 (More Frequent)
Colitis ulcerativeGastrointestinal disorders1/70/111/180/100/110/20/10/20/30/30/30/40/4
Most frequent other events
Showing 10 of 57
Most frequent other events
EventIBT: MK-6194 Low Dose Interval 1 (Less Frequent)IBT-MK-6194 Medium Dose- Interval 2 (More Frequent)IBT: MK-6194 High Dose-Interval 2 (More Frequent)IBT:MK-6194 High Dose-Interval 1 (Less Frequent)IBT: PlaceboCBT: MK-6194 Low Dose- Interval 1 (Less Frequent)CBT: MK-6194 Medium Dose- Interval 2 (More Frequent)CBT: MK-6194 High Dose- Interval 2 (More Frequent)CBT: MK-6194 High Dose - Interval 1 (Less Frequent)CBT: PlaceboOL: MK-6194 Low Dose -Interval 1 (Less Frequent)OL: MK-6194 Medium Dose- Interval 2 (More Frequent)OL: MK-6194 High Dose- Interval 2 (More Frequent)
EosinophiliaBlood and lymphatic system disorders3/77/1117/184/102/111/21/11/21/31/30/33/41/4
Injection site erythemaGeneral disorders5/77/1112/185/100/112/21/12/21/30/31/32/40/4
DiarrhoeaGastrointestinal disorders0/70/110/181/100/111/20/10/20/30/30/30/40/4
VomitingGastrointestinal disorders0/70/110/180/100/111/20/10/20/30/30/30/40/4
Injection site discolourationGeneral disorders0/70/110/180/100/111/20/10/20/30/30/30/40/4
Injection site painGeneral disorders0/70/110/181/100/111/20/10/20/30/30/30/40/4
Injection site pruritusGeneral disorders2/74/112/180/100/110/20/11/20/30/31/31/40/4
Injection site swellingGeneral disorders0/70/110/181/100/111/20/10/20/30/30/30/40/4
Blood bilirubin increasedInvestigations0/70/110/180/100/110/20/11/20/30/30/30/40/4
Weight increasedInvestigations0/70/110/180/100/110/20/10/21/30/30/30/40/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)PlaceboTotal
Mean43.4 ± 11.5943.4 ± 14.6447.7 ± 11.4343.3 ± 10.1135.6 ± 11.8543.2 ± 12.31
Sex: Female, Male
Sex: Female, Male(Participants)MK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)PlaceboTotal
Female4573524
Male36117633
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)PlaceboTotal
Hispanic or Latino200035
Not Hispanic or Latino511189851
Unknown or Not Reported000101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-6194 Low Dose - Interval 1 (Less Frequent)MK-6194 Medium Dose- Interval 2 (More Frequent)MK-6194 High Dose - Interval 2 (More Frequent)MK-6194 High Dose - Interval 1 (Less Frequent)PlaceboTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American010012
White71018101055
More than one race000000
Unknown or Not Reported000000
08

Study locations

17 sites
  • Inland Empire Clinical Trials, LLC ( Site 0102)
    Rialto, California 92377, United States
  • IHS. Health, LLC ( Site 0104)
    Kissimmee, Florida 34741, United States
  • Carolina's GI Research, LLC ( Site 0105)
    Raleigh, North Carolina 27607, United States
  • Pinnacle Clinical Research ( Site 0103)
    San Antonio, Texas 78229, United States
  • Southern Star Research Institute ( Site 0101)
    San Antonio, Texas 78229, United States
  • ARENSIA Exploratory Medicine Georgia ( Site 0801)
    Tbilisi, 0112, Georgia
  • Charite Research Organisation GmbH ( Site 0201)
    Berlin, 10117, Germany
  • PRA Magyarorszag Kutatasi es Fejlesztesi Kft. ( Site 0302)
    Budapest, 1007, Hungary
  • ARENSIA Exploratory Medicine ( Site 0401)
    Chisinau, 2025, Moldova
  • Allmedica Badania Kliniczne Sp z o. o. Sp. K. ( Site 0502)
    Nowy Targ, Lesser Poland Voivodeship 34-400, Poland
  • WIP Warsaw IBD Point Professor Kierkus ( Site 0501)
    Warsaw, Masovian Voivodeship 00-728, Poland
  • Arensia Exploratory Medicine GmbH Ukraine ( Site 0701)
    Kyiv, Kyivska Oblast 01135, Ukraine
  • MAC Clinical Research Prescot ( Site 0604)
    Prescot, Knowsley L34 1BH, United Kingdom
  • Memory Assessment Clinics Ltd ( Site 0601)
    Blackpool, Lancashire FY2 0JH, United Kingdom
  • MAC Clinical Research ( Site 0602)
    Barnsley, S75 3DL, United Kingdom
  • MAC Clinical Research Centre Leeds ( Site 0603)
    Leeds, LS10 1DU, United Kingdom
  • MAC Clinical Research Ltd. ( Site 0605)
    Manchester, M13 9NQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jan 2024, 26 months.

Results were first posted in Mar 2025, 1 year 2 months after primary completion.

Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 26 months is above that.

Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Jun 11, 2021
StartActual
Oct 14, 2021
Primary completionActual
Jan 8, 2024
CompletionActual
Jul 15, 2024
Results first posted
Mar 24, 2025
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04924114
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Oct 14, 2021
Primary completion
Jan 8, 2024
Completion
Jul 15, 2024
Results posted
Mar 24, 2025
Last update
Aug 29, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-6194

Start the discussion